Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 10/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.38 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029708 | 1.00 | PDK1 (0.61) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL2934637 | 1.00 | PDK1 (0.61) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL26135916 | 0.89 | PDK1 (0.63) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL16934686 | 0.89 | PDK1 (0.63) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL1291211 | 0.89 | PDK1 (0.63) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL28132263 | 0.86 | PDK1 (0.62) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL28133029 | 0.86 | PDK1 (0.62) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL27785370 | 0.86 | PDK1 (0.62) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL4725489 | 0.85 | PDK1 (0.45) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB | |
| SCHEMBL26128380 | 0.85 | PDK1 (0.45) | PDK1PIK3CAPIK3CDPIK3R2PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104080335-A | Certain chemical entities, compositions, and methods | QIAN XIANGPING | 2014-10-01 | — | — | CN | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | US | disclosed |
| EP-1421082-A1 | NEW PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003018576-A1 | NEW PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | PDK1 671/4885PIK3CA 502/4885PIK3CD 430/4885 |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | CCR2, CXCR1, CCR5 | PDK1 1465/4885PIK3CA 3548/4885PIK3CD 3063/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | PDK1 1451/4885PIK3CA 3394/4885PIK3CD 3355/4885 |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | CCR5, CCR2, CXCR2 | PDK1 2228/4885PIK3CA 3327/4885PIK3CD 2896/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PDK1 981/4885PIK3CA 78/4885PIK3CD 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.